NCT07365904

Investigating Ovulation Inhibition for Use as a Contraceptive

A Single-centre, Open-label, Phase II Study on the Maintenance of Ovulation Inhibition After Intentional Application Contraceptive

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Mylan Pharmaceuticals Inc · Industry
• Sex: Female
• Age: 18 Years – 35 Years
• Healthy volunteers: Accepted

Summary

A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch

Detailed description

Ovulation inhibition study of MR-130A-01 contraceptive transdermal patch containing norelgestromin with intentional application errors; MR-130A-01-TD-2002

Conditions

• Contraception

Interventions

Type	Name	Description
DRUG	MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)	MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)

Timeline

• Start date: 2025-12-22
• Primary completion: 2026-11-30
• Completion: 2026-11-30
• First posted: 2026-01-26
• Last updated: 2026-01-26

Locations

1 site across 1 country: Germany

Regulatory

• FDA-regulated drug study